Efficacy of rifabutin-loaded microspheres for treatment of Mycobacterium avium-infected macrophages and mice

Drug Delivery

Volumn 14, Issue 3, 2007, Pages 119-127

  Barrow, Esther L W ^a   Barrow, William W ^a   Quenelle, Debra C ^b   Westbrook, Louise ^c   Winchester, Gary A ^c   Staas, Jay K ^c  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b University of Alabama at Birmingham   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Drug Delivery; Intracellular; M. avium; Microspheres; Rifabutin

Indexed keywords

MICROSPHERE; RIFABUTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; EVALUATION; FEMALE; HUMAN; MACROPHAGE; MONOCYTE; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; COLONY COUNT, MICROBIAL; FEMALE; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MICROSPHERES; MONOCYTES; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM PHLEI; PHAGOCYTOSIS; RIFABUTIN; SERUM BACTERICIDAL TEST;

EID: 34247487364     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540600739815     Document Type: Article

References (44)

1. Abrams, E. J. 2000. Opportunistic infections and other clinical manifestations of HIV disease in children. Pediatr. Clin. North Am. 47:79-108.
2. Barrow, E. L. W., Winchester, G. A., Staas, J. K., Quenelle, D. C., and Barrow, W. W. 1998. Use of microsphere technology for sustained and targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob. Agents Chemother. 42:2682-2689.
3. Barrow, W. W. 2004. Microsphere technology for chemotherapy of mycobacterial infections. Curr. Pharmaceut. Design 10:3725-3284.
4. Benson, C. A., Williams, P. L., Cohn, D. L., Becker, S., Hojczyk, P., Nevin, T., Korvick, J. A., et al. 2000. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J. Infect. Dis. 181:1289-1297.
5. Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., and Young, L. S. 2001. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 45(1):217-222.
6. Boyd, A. E., and Brettle, R. P. 1999. Localized Mycobacterium avium intracellulare psoas abscess in patients with AIDS after antiretroviral therapy [letter]. AIDS 13:2185-2186.
7. Brady, J. M., Cutright, D. E., Miller, R. A., and Barristone, G. C. 1973. Resorption rate, route of elimination and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. J. Biomed. Mater. Res. 7:155-166.
8. Brughera, M., Scampini, G., Newman, A. J., Castellino, S., Sammartini, U., and Mazue, G. 1995. Overview of toxicological data on rifabutin. Exp. Toxicol. Pathol. 47:1-9.
9. Chin, D. P., Reingold, A. L., Stone, E. N., Vittinghoff, E., Horsburgh, C. R., Simon, E. M., Yajko, D. M., et al. 1994. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients: a prospective study. J. Infect. Dis. 170(3):578-584.
10. Cinti, S. K., Kaul, D. R., Sax, P. E., Crane, L. R., and Kazanjian, P. H. 2000. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin. Infect. Dis. 30:511-514.
11. Fattorini, L., Hu, C. Q., Jin, S. H., Santoro, C., Tsang, A. Y., Mascellino, M. T., Mandler, F., and Orefici, G. 1992. Activity of antimicrobial agents against Mycobacterium avium-intracellulare complex (MAC) strains isolated in Italy from AIDS-patients. Zentralbl. Bakteriol. 276(4):512-520.
12. Gilding, D. K., and Reed, A. M. 1979. Biodegradable polymers for use in surgery polyglycolic/poly(lactic acid) homo- and copolymers. Polymer 20:1459-1464.
13. Gordin, F. M., Sullam, P. M., Shafran, S. D., Cohn, D. L., Wynne, B., Paxton, L., Perry, K., and Horsburgh, Jr., C. R. 1999. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin. Infect. Dis. 28:1080-1085.
14. Havner, R., Bethel, J., Power, M., Landry, B., Banach, M., Mole, L., Standiford, H. C., et al. 1998. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob. Agents Chemother. 42(3):631-639.
15. Horsburgh, C. R., Jr., Havlik, J. A., Ellis, D. A., Kennedy, E., Fann, S. A., Dubois, R. E., and Thompson, S. E. 1991. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am. Rev. Respir. Dis. 144:557-559.
16. Jacobson, M. A., Hopewell, P. C., Yajko, D. M., Hadley, W. K., Lazarus, E., Mohanty, P. K., Modin, G. W., et al. 1991. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J. Infect. Dis. 164:994-998.
17. Jain, R. A. 2000. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21:2475-2490.
18. Kaplan, J. E., Hanson, D., Dworkin, M. S., Frederick, T., Bertolli, J., Lindegren, M. L., Holmberg, S., and Jones, J. L. 2000. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30:S5-14.
19. Karakousis, P. C., Moore, R. D., and Chaisson, R. E. 2004. Mycobacterium avium complex in patients with HIV infections in the era of highly active antiretroviral therapy. Lancet Infect. Dis. 4 (Sept.):557-565.
20. Klemens, S. P., and Cynamon, M. H. 1991. In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob. Agents Chemother. 35:2026-2030.
21. Klemens, S. P., Grossi, M. A., and Cynamon, M. H. 1994. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob. Agents Chemother. 38:234-237.
22. Koletar, S. L., Berry, A. J., Cynamon, M. H., Jacobson, J., Currier, J. S., MacGregor, R. R., Dunne, M. W., and Williams, D. J. 1999. Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients. Antimicrob. Agents Chemother. 43:2869-2872.
23. Moore, R. D., and Chaisson, R. E. 1995. Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS. AIDS 9:1337-1342.
24. NCCLS. 1995. Antimycobacterial Susceptibility Testing for Mycobacterium tuberculosis, tentative standard. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards.
25. Nightingale, S. D., Byrd, L. T., Southern, P. M., Jockusch, J. D., Cal, S. X., and Wynne, B. A. 1992. Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus positive patients. J. Infect. Dis. 165:1082-1085.
26. Nightingale, S. D., Cameron, D. W., Gordin, F. M., Sullam, P. M., Cohn, D. L., Chaisson, R. E., Eron, L. J., et al. 1993. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N. Engl. J. Med. 329:828-833.
27. Olliaro, P., and Dautzenberg, B. 1994. Control of the body burden of M. avium complex is associated with improved quality of life and prolonged survival of patients with AIDS: a prospective trial with rifabutin combined with isoniazid, clofazimine, ethambutol. J. Chemother. 6(3):189-196.
28. Palella, F. J. Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., and Holmberg, S. D. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
29. Quenelle, D. C., Barrow, E. W., Winchester, G. A., Staas, J. K., Hoskins, D. E., and Barrow, W. W. 2004. Sustained release characteristics of rifampinloaded microsphere formulations in non-human primates. Drug Del. 11:239-246.
30. Quenelle, D. C., Staas, J. K., Winchester, G. A., Barrow, E. L. W., and Barrow, W. W. 1998. Treatment of Mycobacterium tuberculosis with programmedrelease rifampicin-loaded microsphere formulations, abstract B45. Paper read, 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
31. Quenelle, D. C., Staas, J. K., Winchester, G. A., Barrow, E. L. W., and Barrow, W. W. 1999. Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice. Antimicrob. Agents Chemother. 43:1144-1151.
32. Quenelle, D. C., Winchester, G. A., Staas, J. K., Barrow, E. L. W., and Barrow, W. W. 2001. Treatment of tuberculosis using a combination of sustainedrelease rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob. Agents Chemother. 45:1637-1644.
33. Rastogi, N., Potar, M.-C., and David, H. L. 1987. Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J774: ultrastructure and drug-susceptibility studies. Curr. Microbiol. 16:79-92.
34. Sawhney, N. 1999. MAC prophylaxis in the era of polypharmacy. Wisconsin Medical Journal 98:46-48.
35. Schwietert, M., and Battegay, M. 1999. Focal mycobacterial lymphadenitis after starting highly active antiretroviral therapy. Dtsch. Med. Wochenschr 124:45-48.
36. Sharkey, M. E., Teo, I., Greenough, T., Sharova, N., Luzuriaga, K., Sullivan, J. L., Bucy, R. P., et al. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6:76-81.
37. Tice, T. R., and Cowsar, D. R. 1984. Biodegradable controlled-release parenteral systems. J. Pharmaceut. Technol. 8 (Nov.):26-35.
38. Visscher, G. E., Robison, R. L., and Argentieri, G. I. 1987. Tissue response to biodegradable injectable microcapsules. J. Biomat. Appl. 2:118-131.
39. Visscher, G. E., Robison, R. L., Maulding, H. V., Fong, J. W., Pearson, J. E., and Argentieri, G. I. 1985. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J. Biomed. Mat. Res. 19:349-365.
40. Visscher, G. E., Robison, R. L., Maulding, H. V., Fong, J. W., Pearson, J. E., and Argentieri, G. I. 1986. Biodegradation of and tissue reaction to microcapsules. J. Biomed. Mat. Res. 20:667-676.
41. Wong, B., Edwards, F. F., Kiehn, T. E., Whimbey, E., Donnelly, H., Bernard, E. M., Gold, J. W. M., and Armstrong, D. 1985. Continuous high-grade Mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome. Am. J. Med. 78:35-40.
42. Wright, E. L., Quenelle, D. C., Suling, W. J., and Barrow, W. W. 1996. Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrob. Agents Chemother. 40:2206-2208.
43. Wu, X. S. 1995. Synthesis and properties of biodegradable lactic/glycolic acid polymers. In Encyclopedic Handbook of Biomaterials and Bioengineering, ed. Wise, E. A. New York: Marcel Dekker.
44. Ziegler-Heitbrock, H. W. L., Thiel, E., Fütterer, A., Herzog, V., and Wirtz, A. 1988. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer 41:456-461.